Information for the public
Temozolomide (Temodal) is recommended as a possible treatment for people with brain cancer or malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, only if:
the cancer has come back or got worse after standard treatment
the person has a Karnofsky performance status greater than or equal to 70 and
the person is expected to live for 12 weeks or more.
If you have malignant glioma, and your doctor thinks that temozolomide is the right treatment, you should be able to have the treatment on the NHS.
Temozolomide should be available on the NHS within 3 months of the guidance being issued.
If you are not eligible for treatment as described above, you should be able to continue taking temozolomide until you and your doctor decide it is the right time to stop.